Last update 01 Nov 2024

Uproleselan

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Uproleselan (USAN/INN), Uproleselan injection, Uproleselan sodium
+ [2]
Target
Mechanism
E-sel inhibitors(Selectin E inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Breakthrough Therapy (US)
Login to view timeline

Structure

Molecular FormulaC60H109N3NaO27
InChIKeyHHTBXHJWLLMOLI-CVDXTIKBSA-N
CAS Registry1914993-95-5

External Link

KEGGWikiATCDrug Bank
D11332--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapsing acute myeloid leukemiaPhase 2
IT
15 Oct 2018
Relapsing acute myeloid leukemiaPhase 2
NL
15 Oct 2018
Relapsing acute myeloid leukemiaPhase 2
AU
15 Oct 2018
Relapsing acute myeloid leukemiaPhase 2
ES
15 Oct 2018
Relapsing acute myeloid leukemiaPhase 2
CA
15 Oct 2018
Relapsing acute myeloid leukemiaPreclinical
NL
15 Oct 2018
Relapsing acute myeloid leukemiaPreclinical
IT
15 Oct 2018
Relapsing acute myeloid leukemiaPreclinical
ES
15 Oct 2018
Relapsing acute myeloid leukemiaPreclinical
AU
15 Oct 2018
Relapsing acute myeloid leukemiaPreclinical
CA
15 Oct 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
388
(jdqjurhmwk) = qtmeqontif svwxftozox (bwcdqfzifi )
Positive
04 Jun 2024
Placebo
(jdqjurhmwk) = ovkwbkzonc svwxftozox (bwcdqfzifi )
Phase 3
388
(fvanjifamg) = kjlvmaiawt zqfsldfbzs (iwdsmdicrd )
Not Met
Negative
06 May 2024
placebo
(fvanjifamg) = rathnmqzic zqfsldfbzs (iwdsmdicrd )
Not Met
Phase 2
51
(Uproleselan + Standard of Care Melphalan)
jntctvxmjx(lmuzpoqldv) = oixamdnfsr xrnksrtrem (siafuhdwwl, tirtccnieh - oqxhfozbxy)
-
15 Dec 2023
Placebo+melphalan
(Placebo + Standard of Care Melphalan)
jntctvxmjx(lmuzpoqldv) = zfkfffvqsf xrnksrtrem (siafuhdwwl, mqvugluswk - hzayfzqfpo)
Phase 1/2
20
(izwhqrwxqj) = onagamdloj fmkfqyvrhw (nlpjjekovw )
-
10 Dec 2023
Phase 1/2
6
apzpstyhmp(gudbrokqbs) = vyxeffaoxa dihuczgrip (eatxkfrzni, smxdlbufgd - kwvrfmvgsa)
-
10 Jul 2023
Phase 1/2
10
(htfkvkqlcb) = The most common SAEs were ≥ grade 3 neutropenic fever (70%), (including 2 grade 5 events), grade 3 bleeding (10%), and grade 2 thrombosis (5%) idsxpygpth (ohvcqcewyn )
Positive
15 Nov 2022
Phase 1
8
(thoiiutjzr) = hpqatyicvh ppalyyszqo (qbmzscbgfy )
Positive
15 Nov 2022
Phase 1/2
-
Chemotherapy+Uproleselan
(alvjhfrtmy) = 10 mg/kg twice daily viyhnhpiqd (ecwtmxjkzk )
Positive
20 Sep 2021
Phase 2
24
(dsycfcjowj) = cognmadqeg zcrwvlvsrg (mfbiqxxyhi )
-
30 May 2017
Phase 2
24
(ygptcxyyfz) = 47% mqzbpyauqz (nfuigtcmdg )
Positive
18 May 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free